Stock Worth Watching: Could AstraZeneca plc (ADR) Change Direction After Reaching Yearly Low?

Stock Worth Watching: Could AstraZeneca plc (ADR) Change Direction After Reaching Yearly Low?

The stock of AstraZeneca plc (ADR) (NYSE:AZN) hit a new 52-week low and has $25.70 target or 3.00% below today’s $26.49 share price. The 9 months bearish chart indicates high risk for the $65.75 billion company. The 1-year low was reported on Nov, 22 by If the $25.70 price target is reached, the company will be worth $1.97 billion less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 7.12 million shares traded hands or 8.87% up from the average. AstraZeneca plc (ADR) (NYSE:AZN) has declined 9.38% since April 20, 2016 and is downtrending. It has underperformed by 13.94% the S&P500.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Leerink Swann maintained it with “Market Perform” rating and $34 target price in Monday, May 2 report. On Tuesday, October 20 the stock rating was downgraded by Credit Suisse to “Underperform”. The rating was upgraded by Barclays Capital to “Equal-Weight” on Tuesday, January 19. The rating was downgraded by HBSC on Monday, February 8 to “Hold”. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Buy” rating given on Monday, September 14 by Deutsche Bank. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Buy” rating by S&P Research on Friday, July 31. Bryan Garnier & Cie upgraded the stock to “Buy” rating in Friday, September 18 report. The stock has “Buy” rating given by Cantor Fitzgerald on Friday, February 26. Piperjaffray initiated the stock with “Overweight” rating in Friday, September 23 report. As per Friday, July 31, the company rating was upgraded by Swedbank.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by which published an article titled: “AstraZeneca plc (ADR): What Are the Future Prospects?” on August 01, 2016.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment